Skip to main content
OpenTrials

Clinical trial condition

Hematologic Diseases

Explore clinical trials studying Hematologic Diseases. Study availability and eligibility vary by location and protocol.

15,382 public trials 2,843 recruiting studies
Refine in advanced search Browse all conditions

Hematologic Diseases trial results

Recruiting

A Study of Teclistamab and Mezigdomide in People With Multiple Myeloma

NCT07105059

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +16 more
Locations
  • Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) Basking Ridge, New Jersey, United States
  • Memorial Sloan Kettering Monmouth (Limited Protocol Activities) Middletown, New Jersey, United States
  • Memorial Sloan Kettering Bergen (Limited Protocol Activities) Montvale, New Jersey, United States
  • Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities) Commack, New York, United States
View Trial Details
Recruiting

Anti-CD19, Dual Co-stimulatory (4-1BB, CD3ζ) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL)

NCT03938987

Conditions
Hematologic Diseases, Hemic and Lymphatic Diseases, Immune System Diseases, +13 more
Locations
  • Foothills Medical Centre Calgary, Alberta, Canada
  • Tom Baker Cancer Centre Calgary, Alberta, Canada
  • Alberta Children's Hospital Calgary, Alberta, Canada
  • Cross Cancer Institute Edmonton, Alberta, Canada
View Trial Details
Recruiting

A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)

NCT06950034

Conditions
Acute Monocytic Leukemia, Acute Myeloid Leukemia, Acute Myeloid Leukemia (AML), +24 more
Locations
  • Stanford University Stanford, California, United States
  • Moffitt Tampa, Florida, United States
  • DFCI Boston, Massachusetts, United States
  • Mayo Clinic Rochester, Minnesota, United States
View Trial Details
Recruiting

Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)

NCT04895436

Conditions
Chronic Disease, Chronic Lymphocytic Leukemia (CLL), Disease Attributes, +14 more
Locations
  • Moores Cancer Center at UC San Diego /ID# 230157 La Jolla, California, United States
  • Winship Cancer Institute of Emory University /ID# 230643 Atlanta, Georgia, United States
  • Des Moines Oncology Research Association /ID# 232606 Des Moines, Iowa, United States
  • Dana-Farber Cancer Institute /ID# 230061 Boston, Massachusetts, United States
View all 58 locations
View Trial Details

Related conditions